Actionable targets in patients with cisplatin-resistant advanced germ cell tumours

Survival outcomes from the CALGB 40603 study in triple-negative breast cancer

Molecular evolution of breast cancer during neoadjuvant chemotherapy

Homologous recombination deficiency predicts neo-adjuvant chemotherapy response in triple-negative breast cancer

TAILORx: Genomic test helps identify low-risk women who do not need chemotherapy

Editor's choice for December 2015

Update on management of the axilla

Peri-operative lapatinib has profound antiproliferative effect in early breast cancer

Guidelines and management of advanced breast cancer in limited resource settings

New developments and technologies in hereditary cancer

Results of the CREATE-X trial

Improved survival outcomes in women with HER2-negative breast cancer after neoadjuvant chemotherapy